Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Nkarta, Inc.

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Announces Pricing of $240 Million Underwritten Offering
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
Tickers NKTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.